<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2019.8.n682</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-682</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РАЗНОЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>MISCELLANEOUS</subject></subj-group></article-categories><title-group><article-title>Оценка роли показателей окислительного стресса и ранних маркеров повреждения и дисфункции миокарда у больных лимфопролиферативными заболеваниями</article-title><trans-title-group xml:lang="en"><trans-title>Assessment of the Role of Oxidative Stress Indicators and Early Markers of Myocardial Injury and Disfunction in Patients with Lymphoproliferative Diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беленков</surname><given-names>Ю. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Belenkov</surname><given-names>Yu. N.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ершов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ershov</surname><given-names>V. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Антюфеева</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Antyufeeva</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="en"><p>Antyufeeva Olga N. - MD.</p></bio><email xlink:type="simple">olgaantyufeeva86@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буданова</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Budanova</surname><given-names>D. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочкарева</surname><given-names>Ю. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochkareva</surname><given-names>Yu. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москвы</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гадаев</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Gadaev</surname><given-names>I. Yu.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бочкарникова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bochkarnikova</surname><given-names>O. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соколова</surname><given-names>И. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Sokolova</surname><given-names>I. Ya.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириченко</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirichenko</surname><given-names>Yu. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Юлия Юрьевна Кириченко - аспирант кафедры Госпитальной терапии №1 л/ф</p></bio><email xlink:type="simple">Kataraza@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sechenov First Moscow State Medical University (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Городская клиническая больница им. С. П. Боткина» Департамента здравоохранения</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Botkin Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>08</day><month>08</month><year>2019</year></pub-date><volume>59</volume><issue>8</issue><fpage>47</fpage><lpage>53</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/682">https://cardio.elpub.ru/jour/article/view/682</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучить динамику показателей окислительного стресса и их роль в развитии кардиотоксичности у больных лимфопролиферативными заболеваниями на фоне полихимиотерапии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 30 пациентов с впервые выявленными неходжкинскими лимфомами. Группу контроля составили 15 здоровых добровольцев. Для регистрации динамики образования активных форм кислорода лейкоцитами использовали высокочувствительный хемилюминесцентный метод. Состояние стартового этапа липопероксидации, заключающегося в генерации активных форм кислорода (АФК) и радикалов органических соединений, оценивали по динамике хемилюминесценции лейкоцитов. Состояние финального этапа липопероксидации, характеризующегося образованием неметаболизирующихся гидроперекисей липидов и других соединений, оценивали по уровню малонового диальдегида (МДА). Определяли показатель интенсивности хемилюминесценции лейкоцитов базальный (ПИХЛ баз.) и стимулированный зимозаном (ПИХЛ стим.). Для оценки функционального состояния сердечно-сосудистой системы проводили электрокардиографию, эхокардиографию (ЭхоКГ) и суточное мониторирование электрокардиограммы до и после курса химиотерапии.</p></sec><sec><title>Результаты</title><p>Результаты. Получены данные, свидетельствующие о повышенной генерации свободных радикалов лейкоцитами у больных неходжкинскими лимфомами при проведении полихимиотерапии. После курса химиотерапии выявлены различные виды кардиотоксичности. Отмечалось значительное повышение частоты наджелудочковых и желудочковых экстрасистол, при этом выявлена прямая корреляция между уровнем хемилюминесценции лейкоцитов и частотой возникновения наджелудочковой экстрасистолии после проведенного лечения (r=0,7; р=0,03). По данным ЭхоКГ, хотя фракция выброса левого желудочка и оставалась в пределах нормы в ходе полихимиотерапии, отмечалась стойкая тенденция к ее снижению (р&lt;0,001).</p></sec><sec><title>Заключение</title><p>Заключение. В ходе данного исследования впервые выявлено повышение уровня свободнорадикальных реакций и перекисного окисления липидов при одновременном снижении антиперекисной активности плазмы у больных неходжкинскими лимфомами и их взаимосвязь с развитием кардиотоксических эффектов. Полученные результаты указывают на необходимость поиска новых ранних маркеров активации окислительного стресса, дисфункции и повреждения миокарда, которые могут помочь существенно снизить риск развития сердечно-сосудистых осложнений в ходе химиотерапии и после нее.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to study dynamics of indicators of oxidative stress and their role in development of cardiotoxicity in patients with lympho-proliferative diseases at the background of polychemotherapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We included into this study 30 patients with newly detected Non-Hodgkin lymphomas. The control group comprised 15 healthy volunteers. For registration of dynamics of formation of oxygen active forms (OAF), we used highly sensitive chemiluminescence assay. The state of initial stage of lipoperoxidation OAF and radicals of organic compounds) was assessed by dynamics of the leukocyte chemiluminescence. The state of final stage of lipoperoxidation (formation of nonmetabolizing lipid hydroperoxides and other compounds) was assessed by the level of malonic dialdehyde. We also determined indicator of leukocyte chemiluminescence intensity (both basal and zymosan-stimulated). For assessment of the cardiovascular system functional state before and after chemotherapy we used electrocardiography (ECG), echocardiography (EchoCG) and 24-hour ECG monitoring.</p></sec><sec><title>Results</title><p>Results. The data obtained were indicative of increased generation of free radicals by leukocytes during polychemotherapy. After chemotherapy course we detected various types of cardiotoxicity. We noted substantial elevation of frequency of supraventricular and ventricular extrasystoles. There was direct correlation between rate of appearance of supraventricular extrasystoles and level of chemiluminescence of leukocytes (r=0.7; p=0.03). According to data of EchoCG although the left ventricular ejection fraction remained within the normal range during chemotherapy, there was a persistent tendency to its decrease (р&lt;0.001).</p></sec><sec><title>Conclusion</title><p>Conclusion. In this study we for the first time in patients with Non-Hodgkin lymphomas detected an elevation of level of free radical reactions and lipid peroxidation with simultaneous lowering of antiperoxidative activity of blood plasma and their relation to development of cardiotoxic effects. The results obtained indicate to necessity of search for novel early markers of oxidative stress activation, myocardial injury and disfunction able to help to substantially decrease risk of development of cardiovascular complications during and after chemotherapy.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>окислительный стресс</kwd><kwd>кардиотоксичность</kwd><kwd>лимфома</kwd><kwd>хемилюминесценция лейкоцитов</kwd><kwd>малоновый диальдегид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oxidative stress</kwd><kwd>cardiotoxicity</kwd><kwd>lymphoma</kwd><kwd>leukocyte chemiluminescence</kwd><kwd>malonic dialdehyde</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Поддерживается «Проектом повышения конкурентоспособности ведущих российских университетов среди ведущих мировых научно-образовательных центров»</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(l):22-32. DOI: 10.1182/blood-2014-05-577189</mixed-citation><mixed-citation xml:lang="en">.	Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125(l):22-32. DOI: 10.1182/blood-2014-05-577189</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Issa DE, van de Schans SAM, Chamuleau MED, Karim-Kos HE, Wondergem M, Huijgens PC et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica. 2015;100(4):525-33. DOI: 10.3324/haematol.2014.107300</mixed-citation><mixed-citation xml:lang="en">Issa DE, van de Schans SAM, Chamuleau MED, Karim-Kos HE, Wondergem M, Huijgens PC et al. Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010. Haematologica. 2015;100(4):525-33. DOI: 10.3324/haematol.2014.107300</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Woiniak A, Drewa G, Wozniak B, Schachtschabel DO, Mila-Kierzenkowska C, Drewa T et al. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2005;11(1):BR22-29. PMID: 15614186</mixed-citation><mixed-citation xml:lang="en">Woiniak A, Drewa G, Wozniak B, Schachtschabel DO, Mila-Kierzenkowska C, Drewa T et al. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2005;11(1):BR22-29. PMID: 15614186</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sawyer DB. Anthracyclines and Heart Failure. New England Journal of Medicine. 2013;368(12):1154-6. DOI: 10.1056/NEJMcibr1214975</mixed-citation><mixed-citation xml:lang="en">Sawyer DB. Anthracyclines and Heart Failure. New England Journal of Medicine. 2013;368(12):1154-6. DOI: 10.1056/NEJMcibr1214975</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Current Biology. 2014;24(10):R453-62. DOI: 10.1016/j.cub.2014.03.034</mixed-citation><mixed-citation xml:lang="en">Schieber M, Chandel NS. ROS Function in Redox Signaling and Oxidative Stress. Current Biology. 2014;24(10):R453-62. DOI: 10.1016/j.cub.2014.03.034</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tong L, Chuang C-C, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Letters. 2015;367(1):18-25. DOI: 10.1016/j.canlet.2015.07.008</mixed-citation><mixed-citation xml:lang="en">Tong L, Chuang C-C, Wu S, Zuo L. Reactive oxygen species in redox cancer therapy. Cancer Letters. 2015;367(1):18-25. DOI: 10.1016/j.canlet.2015.07.008</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Holmstrom KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nature Reviews Molecular Cell Biology. 2014;15(6):411-21. DOI: 10.1038/nrm3801</mixed-citation><mixed-citation xml:lang="en">Holmstrom KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nature Reviews Molecular Cell Biology. 2014;15(6):411-21. DOI: 10.1038/nrm3801</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brand MD. The sites and topology of mitochondrial superoxide production. Experimental Gerontology. 2010;45(7-8):466-72. DOI: 10.1016/j.exger.2010.01.003</mixed-citation><mixed-citation xml:lang="en">Brand MD. The sites and topology of mitochondrial superoxide production. Experimental Gerontology. 2010;45(7-8):466-72. DOI: 10.1016/j.exger.2010.01.003</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fransen M, Nordgren M, Wang B, Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822(9):1363-73. DOI: 10.1016/j.bbadis.2011.12.001</mixed-citation><mixed-citation xml:lang="en">Fransen M, Nordgren M, Wang B, Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: Implications for human disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822(9):1363-73. DOI: 10.1016/j.bbadis.2011.12.001</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Singal P, Deally C, Weinberg L. Subcellular effects of adria-mycin in the heart: A concise review. Journal of Molecular and Cellular Cardiology. 1987;19(8):817-28. DOI: 10.1016/S0022-2828(87)80392-9</mixed-citation><mixed-citation xml:lang="en">Singal P, Deally C, Weinberg L. Subcellular effects of adria-mycin in the heart: A concise review. Journal of Molecular and Cellular Cardiology. 1987;19(8):817-28. DOI: 10.1016/S0022-2828(87)80392-9</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Погирницкая А.В., Семенкова Г.Н. Хемилюминесцентный анализ генерации АФК нейтрофилами у больных лимфогранулематозом. Сборник «Биохимия опухолевых клеток». 1990:80-1</mixed-citation><mixed-citation xml:lang="en">Pogirnitskaya A.V., Semenkova G.N. Chemiluminescence analysis of ROS generation by neutrophils in patients with lymphogranulomatosis. Book “Biochemistry of cancer cells." 1990;80-1.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Russian: Чердынцева Н.В., Наумов С.А., УДут В.В., Пешкова О.А., Шепеткин И.А. Окислительный метаболизм нейтрофильных гранулоцитов крови при предраке и раке желудка. Вопросы онкологии. 1992;38(2):182-7</mixed-citation><mixed-citation xml:lang="en">Cherdyntseva N.V., Naumov S.A., Udut VV., Peshkova O.A., Shchepetkin I.A. Blood neutrophil granulocytes oxidative metabolism in patients with gastric precancer and cancer. Problems of oncology. 1992;38(2):182-7.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kharazmi A, Nielsen H, Hovgaard D, Borregaard N, Nissen NI. Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma. European Journal of Clinical Investigation. 1991;21(2):219-24. DOI: 10.1111/j.1365-2362.1991.tb01813.x</mixed-citation><mixed-citation xml:lang="en">Kharazmi A, Nielsen H, Hovgaard D, Borregaard N, Nissen NI. Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma. European Journal of Clinical Investigation. 1991;21(2):219-24. DOI: 10.1111/j.1365-2362.1991.tb01813.x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tullgren O, Giscombe R, Holm G, Johansson B, Mellstedt H, Bjorkholm M. Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease. Clinical &amp; Experimental Immunology. 2008;85(3):436-40. DOI: 10.1111/j.1365-2249.1991.tb05745.x</mixed-citation><mixed-citation xml:lang="en">Tullgren O, Giscombe R, Holm G, Johansson B, Mellstedt H, Bjorkholm M. Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease. Clinical &amp; Experimental Immunology. 2008;85(3):436-40. DOI: 10.1111/j.1365-2249.1991.tb05745.x</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Limat S, Daguindau E, Cahn J-Y, Nerich V, Brion A, Perrin S et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxic-ity in patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Pharmacy and Therapeutics. 2014;39(2):168-74. DOI: 10.1111/jcpt.12124</mixed-citation><mixed-citation xml:lang="en">Limat S, Daguindau E, Cahn J-Y, Nerich V, Brion A, Perrin S et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxic-ity in patients with aggressive non-Hodgkin's lymphoma. Journal of Clinical Pharmacy and Therapeutics. 2014;39(2):168-74. DOI: 10.1111/jcpt.12124</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981-8. DOI: 10.1161/CIRCULATIO-NAHA.114.013777</mixed-citation><mixed-citation xml:lang="en">Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981-8. DOI: 10.1161/CIRCULATIO-NAHA.114.013777</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ et al. Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Frontiers in Oncology. 2014;4:277. DOI: 10.3389/fonc.2014.00277</mixed-citation><mixed-citation xml:lang="en">Tian S, Hirshfield KM, Jabbour SK, Toppmeyer D, Haffty BG, Khan AJ et al. Serum Biomarkers for the Detection of Cardiac Toxicity after Chemotherapy and Radiation Therapy in Breast Cancer Patients. Frontiers in Oncology. 2014;4:277. DOI: 10.3389/fonc.2014.00277</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clinical Biochemistry. 2015;48(4-5):223-35. DOI: 10.1016/j.clinbio-chem.2014.10.013</mixed-citation><mixed-citation xml:lang="en">Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clinical Biochemistry. 2015;48(4-5):223-35. DOI: 10.1016/j.clinbio-chem.2014.10.013</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Annals of Oncology. 2005;16(5):798-804. DOI: 10.1093/annonc/mdi152</mixed-citation><mixed-citation xml:lang="en">Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Annals of Oncology. 2005;16(5):798-804. DOI: 10.1093/annonc/mdi152</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M et al. Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis. Cardiovascular Toxicology. 2012;12(2):135-42. DOI: 10.1007/s12012-011-9149-4</mixed-citation><mixed-citation xml:lang="en">Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M et al. Prediction of Anthracycline Cardiotoxicity after Chemotherapy by Biomarkers Kinetic Analysis. Cardiovascular Toxicology. 2012;12(2):135-42. DOI: 10.1007/s12012-011-9149-4</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Mornoj C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Canadian Journal of Physiology and Pharmacology. 2013;91(8):601-7. DOI: 10.1139/cjpp-2012-0398</mixed-citation><mixed-citation xml:lang="en">Mornoj C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Canadian Journal of Physiology and Pharmacology. 2013;91(8):601-7. DOI: 10.1139/cjpp-2012-0398</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tanindi A, Cemri. Troponin elevation in conditions other than acute coronary syndromes. Vascular Health and Risk Management. 2011;7:597. DOI: 10.2147/VHRM.S24509</mixed-citation><mixed-citation xml:lang="en">Tanindi A, Cemri. Troponin elevation in conditions other than acute coronary syndromes. Vascular Health and Risk Management. 2011;7:597. DOI: 10.2147/VHRM.S24509</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales LJ, Moreno F et al. Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors. The Oncologist. 2015;20(8):864-72. DOI: 10.1634/theoncologist.2014-0500</mixed-citation><mixed-citation xml:lang="en">Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales LJ, Moreno F et al. Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors. The Oncologist. 2015;20(8):864-72. DOI: 10.1634/theoncologist.2014-0500</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Zidan A, Sherief LM, El-sheikh A, Saleh SH, Shahbah DA, Kamal NM et al. NT-proBNP as Early Marker of Subclinical Late Cardiotoxicity after Doxorubicin Therapy and Mediastinal Irradiation in Childhood Cancer Survivors. Disease Markers. 2015;2015:1-10. DOI: 10.1155/2015/513219</mixed-citation><mixed-citation xml:lang="en">Zidan A, Sherief LM, El-sheikh A, Saleh SH, Shahbah DA, Kamal NM et al. NT-proBNP as Early Marker of Subclinical Late Cardiotoxicity after Doxorubicin Therapy and Mediastinal Irradiation in Childhood Cancer Survivors. Disease Markers. 2015;2015:1-10. DOI: 10.1155/2015/513219</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M et al. Serial measurements of NT-proBNP are predictive of nothigh-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer. 2011;105(11):1663-8. DOI: 10.1038/bjc.2011.439</mixed-citation><mixed-citation xml:lang="en">Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M et al. Serial measurements of NT-proBNP are predictive of nothigh-dose anthracycline cardiotoxicity in breast cancer patients. British Journal of Cancer. 2011;105(11):1663-8. DOI: 10.1038/bjc.2011.439</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
